We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Test Detects Mutations Contributing to Blood Coagulation Disorders

By Biotechdaily staff writers
Posted on 23 Oct 2007
A nucleic acid test detects disease-associated gene mutations that can contribute to blood coagulation disorders and difficulties metabolizing folate (vitamin B-12).

The Verigene F5 / F2 / MTHFR (methylenetetrahydrofolate reductase) nucleic acid test identifies mutations in three specific genes that together can increase an individual's risk for dangerous blood clots and their leading complication, stroke.

According to the U.S. National Hemophilia Foundation, more than 600,000 Americans die from abnormal blood clots each year. Patients that test positively for an increased risk of blood clots can be managed with anti-coagulant therapy such as warfarin. Hyper-coagulation tests for mutations associated with a predisposition to blood clots are currently among the most frequently conducted human genetic tests.

The test is available in single and multi target (multiplex) formats, allowing users to select the test cartridge that best fits the clinical indications for testing. The Verigene system's simplicity, ease of use and flexibility allow customers to perform molecular diagnostic testing in virtually any setting.

Nanosphere, Inc. (Northbrook, IL, USA) announced that it has received clearance from the U.S. Food and Drug Administration (FDA; Rockville, MD, USA) for the Verigene F5 / F2 / MTHFR A nucleic acid test. This marks the second nanotechnology-based assay cleared by the FDA to run on the Verigene system, following clearance in September 2007, of the company's Verigene warfarin metabolism nucleic acid test.

Nanosphere is developing molecular diagnostics with a nanotechnology-based platform that will enable earlier detection and treatment of disease. The company's direct genomic testing and ultra-sensitive protein detection technologies permit the development of new biomarkers and measurement of existing biomarkers at concentrations undetectable by today's diagnostic technologies.


Related Links:
Nanosphere, Inc.
U.S. Food and Drug Administration

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
All-in-One Molecular System
AIO M160
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA

Latest BioResearch News

D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
23 Oct 2007  |   BioResearch

New Genetic Cause Identified for Neurodevelopmental Disorder
23 Oct 2007  |   BioResearch

New Genetic Discovery Could Support Precision Diabetes Care
23 Oct 2007  |   BioResearch